2月21日《自然医学》披露的特殊病例引发全球关注：一位接受CAR-T治疗的多发性骨髓瘤患者，竟在9个月后遭遇外周T细胞淋巴瘤的突袭。这场抗癌疗法引发的"细胞叛变"，揭开了现代免疫治疗最隐秘的基因暗战。

Unlike monoclonal antibodies, bispecific antibodies bind to 2 different antigens simultaneously,[1][1] directing T cells toward cancer cells to exert a cytotoxic killing effect.[1][1] Bispecific ...

National Biotechnology Conference, gene therapies, bispecific antibodies and other novel modalities—relative newcomers to ...

With Lava Therapeutics still smoldering from the decision to dump its lead blood cancer drug, the biotech is now laying off ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...

Two of Bambusa’s bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in ...

At the recent 2025 congress of the European Crohn’s and Colitis Organisation, researchers from Helixon Therapeutics presented the discovery and preclinical characterization of HXN-1002, a bispecific ...

Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.

Under the agreement, Summit will supply ivonescimab – an investigational PD-1/VEGF bispecific antibody – for the studies, while Pfizer will oversee study operations. Both companies will ...

Advisor engaged in evaluating strategic options to maximize shareholder valueCash balance of $76.6 million as of December 31, 2024UTRECHT, The ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...